Innovative Cellular Therapeutics (ICT)

Innovative Cellular Therapeutics Co. Ltd (ICT, formerly Sidansai) is a clinical stage, VC backed cell therapy company based in Shanghai, China. The company was founded in 2009. ICT has established a broad portfolio of CAR-T products to treat cancer patients. The proprietary CD19CAR has achieved outstanding clinical results in treating late-stage leukemia and lymphoma patients who failed to respond to standard of care therapies. Several milestones of investigator-initiated trials are provided below: • In July 2015, a first B-ALL patient treated with ICT’s proprietary CAR-T achieved complete remission. • In July 2017, first NHL patient achieved complete remission.• In December 2017, ICT completed investigator-initiated trials for 39 patients with Relapse/Refractory B-ALL. The multi-centered CD19CAR clinical trial was conducted in strict accordance with international standards and monitored by a third party clinical research organization (CRO). • 33/39 patients achieved CR (85%). • Minimal residual disease (MRD) negative rate was 80%. • 6-month overall survival rate was 69%. • 11/39 (28%) patients experienced grade ¾ CRS, and only 2/39(5%) patients experienced grade ¾ neurotoxicity.